Medtech
Leo Cancer Care
Listed/Unlisted: Unlisted
Product area: Upright radiation therapy positioning
First Investment: 2026
Our long-term view: Leo Cancer Care is demoractizing both the proton and the photon radiation therapy market through lower CAPEX, OPEX and higher throughput for clinics. Having already gained traction at larger and smaller clinics, the company is well on the way to becoming a new household name within hardware for radiation therapy.
Occlutech
Listed/Unlisted: Unlisted
Product Area: Interventional Cardiology
First Investment: 2021
Our long-term view: Has a profitable base business within the Occluder space and, on top, structural growth case opportunities in, for instance, heart failure. The company is one of the market leaders in Europe and where the US market serves as an untapped potential for the company.
Perpetua Medical
Listed/Unlisted: Listed
Product Area: Serial acquirer in the healthcare sector
First Investment: 2024
Our long-term view: Nolsterby Invest is an active owner and the re-founder of Perpetua Medical that aims to become a serial acquirer of profitable businesses within the healthcare sector. The company will apply a decentralized ownership model, where the decision-making and operations take place in independent subsidiaries. The time horizon is long-term without any explicit exit strategy and is reflected in the company name.
Diagnostics
Dvysr
Listed/Unlisted: Listed
Product Area: Genetic Test Kits
First Investment: 2023
Our long-term view: Consistent high growth with attractive gross margins over the last few years is likely to continue. A strong cash position allows for exploring the untapped US market in NGS.
Biotech
Akiram Therapeutics
Listed/Unlisted: Unlisted
Product Area: Radiotherapeutics
First Investment: 2022
Our long-term view: Has shown excellent preclinical data with its highly specific antibody, which is attached to a radioactive substance. The target receptor is expressed on several solid tumors, including in orphan indications.
TIRmed Pharma
Listed/Unlisted: Unlisted
Product Area: Atopic Dermatitis
First Investment: 2024
Our long-term view: An unique, first-in-class drug candidate that has shown good preclinical data.
Life Science Tools & Supplies
Peptisystems
Listed/Unlisted: Unlisted
Product Area: Instruments for synthesis of Peptide and Oligonucleotide therapeutics
First Investment: 2023
Our long-term view: Stable and potentially also structural demand in both peptide and oligonucleotide therapeutics, driven by precision medicine and efficacious drugs for large metabolic disorders (e.g., obesity).
Healthtech
Collective Minds Radiology (CMR)
Listed/Unlisted: Unlisted
Product Area: Community and collaboration platform for radiologists
First Investment: 2024
Our long-term view: CMR has a great business idea built on collaboration and knowledge sharing between radiologists worldwide. The correlation between starting new, larger projects on the platform and increased subscription revenue is strong. Ultimately, an increase in the user base makes the platform more valuable to the users; the network effects are profound.
Non-Healthtech
Younium
Listed/Unlisted: Unlisted
Product Area: SaaS Subscription Management
First Investment: 2022
Our long-term view: Enabler of better subscription management and where we see a structural growth trend in SaaS as a delivery model.
Disclaimer
We only present our own view of our holdings and we can sell our buy when ever we believe the long-term view have changed or we believe other assets offer a better return. The company above is not recommendations and we are not displaying our entire portfolio.
We are under no obligations to display our entire portfolio and take no responsibility for the investment decisions other invididuals make based on the information displayed on this website.
The page is updated as of: 2025-07-09